Episode
Episode 166 - Shawn Singh - CEO at Vistagen
- Podcast
- The BioHub - by Avetix
- Published
- May 1, 2026
- Duration seconds
- 1598
- Processing state
not_requested- Canonical source
- https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-166---Shawn-Singh---CEO-at-Vistagen-e3io8p5
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-166-shawn-singh-ceo-at-vistagen/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-166-shawn-singh-ceo-at-vistagen.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of The BioHub Podcast by Avetix , Ben sits down with Shawn Singh, CEO of Vistagen Therapeutics, to discuss his career across biotech, venture capital, CROs, public markets, and the evolution of neuropsychiatry drug development. With more than 30 years of experience spanning private and public biotechnology, medtech, pharma, venture capital, and contract research, Shawn brings a uniquely broad perspective on what it takes to build and lead companies through different stages of growth. In this conversation, Shawn shares reflections on the lessons learned from building and financing life sciences companies, leading through changing market cycles, and staying focused on long-term value creation in CNS. He also discusses Vistagen’s approach to developing differentiated treatments for anxiety, depression, and other neuropsychiatric disorders, the importance of patient need in shaping strategy, and what it takes to advance innovation in an area where new treatment options are urgently needed.